Maat Pharma. -€0.04 -0.53% Friday 15:30
1D 1W 1M 3M 1Y 5Y
11 Apr Expected
This list is based on the watchlists of people on Stock Events who follow MAAT.PA. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Serve Robotics
SERV
Mkt Cap 97.57M
Seres Therapeutics, Inc. focuses on microbiome therapeutics, directly competing in the same space as Maat Pharma with its microbiome restoration therapy products. Regenxbio
RGNX
Mkt Cap 619.64M
REGENXBIO Inc. is involved in gene therapy, which includes treatments that could overlap with Maat Pharma's microbiome-based approaches for certain diseases. Vertex Pharmaceuticals
VRTX
Mkt Cap 126.85B
Vertex Pharmaceuticals Incorporated works on creating new therapies for treating cystic fibrosis and other serious diseases, potentially competing in indications Maat Pharma targets with its microbiome solutions. Synlogic
SYBX
Mkt Cap 18.15M
Synlogic, Inc. is pioneering synthetic biotic medicines, directly competing in the innovative treatment space, including microbiome engineering, similar to Maat Pharma's focus. Forte Biosciences
FBRX
Mkt Cap 21.5M
Fortress Biotech, Inc. is involved in the development of novel pharmaceutical therapies, including areas that might overlap with Maat Pharma's microbiome therapeutic applications. Evelo Biosciences
EVLO
Mkt Cap 0
Evelo Biosciences, Inc. focuses on developing microbiome-based therapies, making it a direct competitor in the field of microbiome science like Maat Pharma. Seres Therapeutics
MCRB
Mkt Cap 185.52M
Seres Therapeutics, Inc. (duplicate entry for SERV, focusing on microbiome therapeutics, directly competing with Maat Pharma in microbiome restoration therapy products).
Ardelyx, Inc. develops drugs for gastrointestinal and cardio-renal diseases, areas where microbiome therapies developed by Maat Pharma could be applied. Galmed Pharmaceuticals
GLMD
Mkt Cap 1.54M
Galmed Pharmaceuticals Ltd. works on liver diseases and metabolic disorders, potentially competing with Maat Pharma's microbiome-based treatments for similar conditions.
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Show more...